Ginkgo Bioworks Holdings, Inc. (DNA) Financials
NYSE:DNAMarket Cap
3.82B
| Metric | 2001 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| 98,285,000 | 54,184,000 | 76,657,000 | 313,837,000 | 477,706,000 | |
| -- | -- | 15,611,000 | 129,690,000 | 204,216,000 | |
| 98,285,000 | 54,184,000 | 61,046,000 | 184,147,000 | 273,490,000 | |
| 100,476,000 | 96,299,000 | 159,767,000 | 1,149,662,000 | 1,052,643,000 | |
| -- | -- | -- | -- | -- | |
| 77,393,000 | 29,483,000 | 38,306,000 | 862,952,000 | 1,429,799,000 | |
| 77,393,000 | 29,483,000 | 38,306,000 | 862,952,000 | 1,429,799,000 | |
| 177,869,000 | 125,782,000 | 198,073,000 | 2,012,614,000 | 2,482,442,000 | |
| -234,508,000 | -71,598,000 | -137,027,000 | -1,828,467,000 | -2,208,952,000 | |
| -- | -48,237,000 | 12,193,000 | -9,655,000 | 87,553,000 | |
| -219,712,000 | -81,046,000 | -107,515,000 | -1,877,571,000 | -2,180,394,000 | |
| 14,796,000 | -9,448,000 | 29,512,000 | -49,104,000 | 28,558,000 | |
| -- | 5,756,000 | 2,582,000 | 837,000 | 20,262,000 | |
| -- | 2,421,000 | 2,385,000 | 2,373,000 | 106,000 | |
| -- | -119,835,000 | -124,834,000 | -1,838,122,000 | -2,121,399,000 | |
| -- | 22,000 | 1,889,000 | -1,480,000 | -15,027,000 | |
| -- | -119,857,000 | -126,723,000 | -1,836,642,000 | -2,106,372,000 | |
| -- | -0.081 | -0.085 | -1.35 | -1.25 | |
| -- | -0.081 | -0.085 | -1.35 | -1.25 | |
| -- | 1,485,061,236 | 1,485,061,236 | 1,359,848,803 | 1,679,061,465 | |
| -- | 1,485,061,236 | 1,485,061,236 | 1,360,373,343 | 1,679,838,849 | |
| 177,869,000 | 125,782,000 | 213,684,000 | 2,142,304,000 | 2,686,658,000 | |
| -- | 1,574,000 | 16,125,000 | -1,733,000 | 7,634,000 |
Key Facts
Industry
Biotechnology
Sector
Healthcare
Headquarters
Boston, MA, US
Website
CEO
Dr. Jason Kelly
Employees
1292
About the Company
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.